BT6

BT6 is a novel small molecule therapeutic candidate currently under development by Bycus Therapeutics, a biotechnology company focused on enzyme engineering and novel drug discovery. Positioned within the company's metabolic disorders program, BT6 is categorized as a "Novel Molecule" asset, distinguishing it from the company's enzyme-based candidates. While the specific molecular target and pharmacological mechanism of action have not been publicly disclosed, BT6 represents a key component of Bycus Therapeutics' proprietary pipeline aimed at addressing unmet needs in metabolic health. As of early 2024, the candidate is in the early stages of development.